Poulsen Henrik Enghusen, Grønlykke Thor Buch
Klinisk Farmakologisk Afdeling Q 7642, H:S Rigshospitalet, DK-2100 København ø.
Ugeskr Laeger. 2003 Apr 14;165(16):1674-6.
Exclusively private companies do drug development. The State contributes with education of academics and basic research constituting the basis of half of the drugs developed by the private companies. The Danish private drug research amounts to six billion DKK per year, corresponding to the estimated price of the development of one new drug. The development shows a negative tendency. There are doubts about the scientific credibility, the number of new drugs is declining, drug development costs are rising, and the competitiveness in Europe is declining compared with the one of The United States. Continued improvement of Danish drug development can be achieved by stimulation of the public research related to drug development.
只有私人公司进行药物研发。国家通过对学术人员的教育和基础研究做出贡献,而基础研究构成了私人公司所研发药物的一半基础。丹麦的私人药物研究每年达60亿丹麦克朗,相当于一种新药研发的预估成本。这种发展呈负面趋势。人们对其科学可信度存疑,新药数量在减少,药物研发成本在上升,与美国相比,丹麦在欧洲的竞争力也在下降。通过刺激与药物研发相关的公共研究,可以实现丹麦药物研发的持续改进。